CYD-TDV
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 27 trials | ||||||
| Phase 2 | NCT02824198 | Jul 2016 → Mar 2017 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT01550289 | Mar 2012 → Dec 2013 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT01488890 | Dec 2011 → Sep 2013 | Dengue hemorrhagic fever, yellow fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT01187433 | Aug 2010 → Oct 2012 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00993447 | Oct 2009 → Sep 2011 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00788151 | Sep 2008 → Feb 2010 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00740155 | Aug 2008 → Oct 2009 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT01374516 | Jun 2011 → Nov 2014 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01373281 | Jun 2011 → Aug 2014 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01254422 | Dec 2010 → Sep 2012 | Dengue hemorrhagic fever | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01134263 | Oct 2010 → Nov 2012 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYD-TDV | “In a randomized, placebo-controlled, monocenter, observer blinded study conducted in an area where dengue is endemic, we assessed the safety and immunogenicity of a...” PMID 22863660 ↗ Jul 201210“The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in...” PMID 31464558 ↗ Nov 2019 “Two groups received an injection at each timepoint of a tetravalent blend of CYD-1;3;4 and a VERO cell derived, live attenuated vaccine against serotype 2 (VDV-2), or the...” PMID 25483647 ↗ 2014 “This study evaluated the safety and immunogenicity of a candidate recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in 9-16 year olds in Latin America.” PMID 24067553 ↗ Oct 2013 “Immunogenicity and safety of a recombinant, live-attenuated, tetravalent dengue disease vaccine (CYD-TDV) was evaluated in children/adolescents in Brazil.” PMID 24189367 ↗ Nov 2013 “The recombinant yellow fever-17D-dengue virus, live, attenuated, tetravalent dengue vaccine (CYD-TDV) has undergone extensive clinical trials.” PMID 26279339 ↗ Aug 2015 “We evaluated the immunogenicity and safety of recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in Indian adults.” PMID 26291554 ↗ 2016 “The live attenuated tetravalent dengue vaccine (CYD-TDV) is licensed using a 0-, 6- and 12-month schedule in dengue-endemic areas.” PMID 30241510 ↗ Sep 2018 “We evaluated the safety and immunogenicity of Phase III lots of a candidate vaccine (CYD-TDV) in children in Malaysia.” PMID 24135573 ↗ Oct 2013 “receive three injections of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV), or placebo” PMID 25018116 ↗ Jul 2014 “receive three injections of recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) or placebo” PMID 25365753 ↗ Nov 2014 |
| Known as | CYD dengue vaccine | “The aim of the study was to assess the efficacy of Sanofi Pasteur's CYD dengue vaccine in preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas...” NCT01374516 ↗1“The aim of the trial was to assess the efficacy of the CYD dengue vaccine in preventing symptomatic, virologically-confirmed dengue (VCD) cases.” NCT01373281 ↗ |
| Known as | Dengvaxia | “The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in...” PMID 31464558 ↗ Nov 20192“Two large pivotal phase III studies demonstrated the efficacy of the tetravalent dengue vaccine (CYD-TDV; Dengvaxia®, Sanofi Pasteur) against all dengue serotypes.” PMID 28598256 ↗ Jun 2017 “vaccination with the tetravalent dengue vaccine (CYD-TDV; Dengvaxia) may bias the diagnosis of dengue” PMID 29300876 ↗ Apr 2018 |
| Modality | Vaccine | “tetravalent CYD vaccine” PMID 25483647 ↗ 2014 |
| Route | Subcutaneous | “0.5 mL, Subcutaneous (SC)” NCT00740155 ↗ |